Needham Reiterates Hold on Fate Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Hold rating on Fate Therapeutics (NASDAQ:FATE).
August 14, 2024 | 9:30 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst Gil Blum has reiterated a Hold rating on Fate Therapeutics. This suggests that the analyst does not see significant upside or downside potential in the short term.
The Hold rating indicates that the analyst believes the stock is fairly valued at its current price. This typically suggests limited short-term price movement, either up or down.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100